APOE and Mental deterioration: In contrast, a large study with rosiglitazone at 3 different doses over 24 weeks revealed significant cognitive improvement at the highest dose (8 mg) in APOE ε4 non-carriers, whereas APOE ε4 carriers experienced some cognitive decline [333].